Search
Zonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigational[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors … [L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan.
Roxithromycin
go.drugbank.com/drugs/DB00778ApprovedInvestigationalWithdrawnRoxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. … It was shown to be more effective against certain Gram-negative bacteria, particularly _Legionella pneumophila_.
Synonyms: (9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime)International brands: Neo-Suxigal, Ao Ge ShenHuman vaccinia virus immune globulin
go.drugbank.com/drugs/DB14112ApprovedInvestigationalThe IgG fraction is purified by the anion-exchange column chromatography method and the solution is solvent/detergent-treated to sterilize the compound [A33814]. … Most compounds used currently are intravenous formulations, which contain no preservatives - unlike prior intramuscular compounds which contained thiomersal, a mercury derivative preservative that could
Tramadol
go.drugbank.com/drugs/DB00193ApprovedInvestigationalTramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the … [A4269,A183842] Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Noax uno 100 mg Retardtabletten, TRAMADOL SANDOZ UNO 150MGIdecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003] … [A232563] These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.
Pancrelipase lipase
go.drugbank.com/drugs/DB13147ApprovedInvestigational[A32748] The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510] … [L2509] The pancrelipase lipase is an enzyme secreted by the pancreas that is responsible for the hydrolysis of dietary fat molecules in the human digestive system.
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalIt was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … [L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945]
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … by the U.S.
Lasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnLasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. … It gained approval by European Commission in March 2009.
Droxicam
go.drugbank.com/drugs/DB09215ApprovedWithdrawnDroxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of [DB00554]. … It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic